A customized program designed for your family.
Sub-specialist supervised
It's not about the medication
It's not about the medication
The Pediatric Endocrine Society position statement suggests that either a Pediatric Endocrinologist manage the use of GLP-1 medications or be consulted.
It's not about the medication
It's not about the medication
It's not about the medication
Our program's goal is to impact on patient and family lifestyle. Medication is just one aspect but the focus will be on nutrition, reducing screen time and increasing physical activity.
Age & stage appropriate
It's not about the medication
Age & stage appropriate
Treatment of obesity in the pediatric population is approved exclusively for adolescents 12 years and above with morbid obesity and other related risk factors.
Medications approved for adolescents
In December 2022 the FDA approved the use of semaglutide under the commercial name Wegovy for use in adolescents 12 years and older who have significant obesity which is defined as a BMI or body mass index above the 95% for their age and sex
Semaglutide: How does it work?
Semaglutide works by mimicking a naturally occurring hormone called glucagon-like peptide-1 (GLP-1), which helps regular blood sugar levels by stimulating insulin production in the pancreas and slowing down stomach emptying. This leads to a feeling of fullness and reduced appetite. Te medication is used in obesity and type 2 diabetes.
Semaglutide: Monitoring effectiveness of treatment and potential side effects
Monitoring of the medication by a specialist is essential. The most commonly seen side effects are ; vomiting, diarrhea, abdominal pain, and constipation. in less than 1% however pancreatitis has been reported.
Semaglutide: Research Studies
A New England journal of medicine article from December of 2022 found that in adolescents injecting semaglutide weekly for 68 weeks while simultaneously changing lifestyle reduced their body mass index by an average of 16%.